Celldex Therapeutics, Inc. (NASDAQ:CLDX) saw unusually-high trading volume on Friday . Approximately 832,475 shares were traded during mid-day trading, a decline of 42% from the previous session’s volume of 1,432,870 shares.The stock last traded at $2.64 and had previously closed at $2.76.

CLDX has been the topic of several research reports. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research report on Tuesday, July 11th. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Cowen and Company reissued a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, June 6th. Finally, BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. Celldex Therapeutics currently has a consensus rating of “Hold” and an average price target of $7.32.

The company’s market cap is $333.69 million. The company’s 50-day moving average is $2.43 and its 200-day moving average is $2.88.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.05. The firm had revenue of $3.83 million during the quarter, compared to analyst estimates of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The business’s revenue was up 175.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.32) EPS. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post ($1.04) EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in CLDX. Vanguard Group Inc. raised its position in shares of Celldex Therapeutics by 7.8% during the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock valued at $24,143,000 after buying an additional 708,095 shares during the last quarter. Meditor Group Ltd raised its position in shares of Celldex Therapeutics by 39.9% during the second quarter. Meditor Group Ltd now owns 5,800,000 shares of the biopharmaceutical company’s stock valued at $14,326,000 after buying an additional 1,654,100 shares during the last quarter. State Street Corp raised its position in shares of Celldex Therapeutics by 4.7% during the first quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock valued at $16,341,000 after buying an additional 202,375 shares during the last quarter. Northern Trust Corp raised its position in shares of Celldex Therapeutics by 12.2% during the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock valued at $4,992,000 after buying an additional 219,661 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Celldex Therapeutics by 42.4% during the first quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock valued at $6,166,000 after buying an additional 508,217 shares during the last quarter. 56.69% of the stock is owned by hedge funds and other institutional investors.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/08/celldex-therapeutics-inc-cldx-sees-strong-trading-volume-2.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.